Epilepsia partialis continua successfully treated with levetiracetam

Haase, Claus G.; Hopmann, Benjamin

doi:10.1007/s00415-009-5043-4

Cited by 6 publications

(8 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Although the approval for the intravenous formulation was “for the treatment of patients with epileptic seizures who are temporary unable to swallow,” it has been widely used since its availability to treat all forms of acute seizures and status epilepticus. Reports of several open case series in adults and children have been published since 2007 (Farooq et al., 2007; Schulze‐Bonhage et al., 2007; Altenmuller et al, 2008; Callen‐Soto et al, 2008; Goraya et al., 2008; Knake et al., 2008; Ruegg et al., 2008; Abend et al, 2009; Berning et al, 2009; Beyenburg et al, 2009; Cilio et al, 2009; Gallentine et al, 2009; Gamez‐Leyva et al, 2009; Haase & Hopmann, 2009; Haberlandt et al, 2009; Kirmani et al, 2009; Trinka & Dobesberger, 2009; Fattouch et al, 2010; Reiter et al, 2010; Weber, 2010; Aiguabella et al., 2011; Chen et al., 2011.…”

Section: Levetiracetammentioning

confidence: 99%

What is the evidence to use new intravenous AEDs in status epilepticus?

Trinka

2011

Epilepsia

View full text Add to dashboard Cite

Summary Current standard treatment of established status epilepticus after failure of benzodiazepines is intravenous phenytoin/fosphenytoin, phenobarbital, or valproate. Since 2006 two new antiseizure drugs have become available as intravenous formulation: levetiracetam (2006) and lacosamide (2008). Both drugs have been taken up very rapidly by the clinicians to treat acute seizures and status epilepticus, despite lack of evidence from randomized controlled trials. The favorable pharmacokinetic profile and the good tolerability, especially the lack of sedating effects of both drugs make them promising potential alternatives to the standard antiseizure drugs. Future randomized controlled trials are needed to inform clinicians better about the best choice of treatment in established status epilepticus. The experimental evidence as well as the current clinical experience with levetiracetam and lacosamide are summarized in this review.

show abstract

Section: Levetiracetammentioning

confidence: 99%

What is the evidence to use new intravenous AEDs in status epilepticus?

Trinka

2011

Epilepsia

View full text Add to dashboard Cite

show abstract

“…To our knowledge, there are as yet only two reports in the literature demonstrating successful treatment of EPC with perampanel in adult patients (table 2). [6,7,11] Focal resection Focal cortical dysplasia [12] Sturge-Weber syndrome [40] Subpial dissection Rasmussen encephalitis [40] Neurostimulation Chronic cortical stimulation Unknown Old ischemic insult [19] rTMS Non-specific [20] tDCS POLG-related mitochondrial disease Autoimmune epilepsy [21] [41] Vagus nerve stimulation Rasmussen encephalitis Chronic inflammatory encephalitis [18] AEDs Perampanel Meningioma [42] Rasmussen encephalitis [43] Levetiracetam Oligodendroglioma [22] ICH [23] Non-specific [10] Topiramate Non-specific [24] Lacosamide Subdural hematoma [25] Primidone Unknown [26] Immunotherapy Immunomodulatory treatments Rasmussen encephalitis [13] Others Botulinum toxin Rasmussen encephalitis [14] Anaplastic astrocytoma [16] Metabolic correction Non-ketotic hyperglycemia [15] [17] AEDs: antiepileptic drugs; ICH: intracerebral hemorrhage; rTMS: transcranial magnetic stimulation; tDCS: transcranial direct current stimulation. In this article, we report the successful treatment of EPC in two pediatric patients, one with NCL and the other with POLG-related mitochondrial disease.…”

Section: Discussionmentioning

confidence: 99%

“…Vagus nerve stimulation Rasmussen encephalitis Chronic inflammatory encephalitis [18] AEDs Perampanel Meningioma [42] Rasmussen encephalitis [43] Levetiracetam Oligodendroglioma [22] ICH [23] Non-specific [10] Topiramate Non-specific [24] Lacosamide Subdural hematoma [25] Primidone Unknown [26] Immunotherapy Immunomodulatory treatments Rasmussen encephalitis [13] Others Botulinum toxin Rasmussen encephalitis [14] Anaplastic astrocytoma [16] Metabolic correction Non-ketotic hyperglycemia [15] [17] AEDs: antiepileptic drugs; ICH: intracerebral hemorrhage; rTMS: transcranial magnetic stimulation; tDCS: transcranial direct current stimulation.…”

Section: Type Of Treatment Treatment Etiology Referencementioning

confidence: 99%

Successful treatment of epilepsia partialis continua with perampanel: two pediatric cases

Mir¹,

Almudhry²,

Al-Ghamdi³

et al. 2021

Epileptic Disorders

View full text Add to dashboard Cite

Epilepsia partialis continua (EPC) is a form of focal motor status epilepticus, associated with multiple etiologies. Etiology-specific treatments, such as hemispherotomy for Rasmussen encephalitis, lesionectomy for focal cortical dysplasia, and metabolic correction for non-ketotic hyperglycemia, have proven to be efficacious in treating EPC, but, in general, EPC is difficult to treat and often drug-resistant, and there is little evidence to guide therapy. We report the successful treatment of EPC with perampanel in two pediatric patients. The first patient was a 12-yearold boy with neuronal ceroid lipofuscinosis (NCL) who started to have EPC around the age of 10 years, characterized by left hemifacial myoclonic twitches and hemibody jerks that were almost continuous throughout the day and disappeared during sleep. He had failed several antiepileptic drugs (AEDs). The EPC stopped within three days of initiating perampanel. The second patient was a six-year-old boy with POLG-related mitochondrial disease who presented to the emergency room with continuous jerky movements of the right arm and face after a trivial head injury. After failing several AEDs, including a midazolam drip, the EPC was controlled with perampanel. Both patients showed dramatic improvement and continue to show sustained efficacy after around five months of follow-up. Based on our observations, perampanel, which has a unique mechanism of action, appears to be a promising therapeutic option for treating EPC.

show abstract

“…Daha öncede literatürde EPK olgularında levetiresetamın başarılı olduğu yönünde raporlar vardır. [9,10] Yine literatürde NKH'de insülin uygulaması ile antiepileptik ilaçlara direnç gösteren nöbetlerin kontrol altına alınabildiği rapor edilmiştir. [2] Epilepsia parsiyalis kontinua olgularında etiyolojik neden olarak NKH'nin akılda tutulması önemlidir.…”

Section: Discussionunclassified

An Etiological Cause of Epilepsia Partialis Continua that Should Not be Forgotten: Hyperglycemia

Şen¹,

Özkan²,

Karaman³

2014

Epilepsi

View full text Add to dashboard Cite

126Halil Murat ŞEN, Adile ÖZKAN, Handan Işın ÖZIŞIK KARAMAN ÖzetEpilepsia parsiyalis kontinua genelde vücudun tek tarafına lokalize klonik jerklerin sattlerden, aylara dek sürebildiği tedaviye dirençli olabilen epileptik nöbettir. Yetişkin yaş grubunda etiyolojide beyin iskemik lezyonları, yer kaplayıcı lezyonları, enfeksiyonları mutlaka ekarte edilmelidir. Tanı konması daha kolay olan metabolik bozukluklar özellikle hiperosmolar nonketotik hiperglisemi etiyolojide unutulmamalıdır. Çünkü nonketotik hiperglisemi olgularının önemli bir kısmında epilepsia parsiyalis kontinua gelişmektedir hatta diyabet tanısı almamış bazı hastalarda diyabetin ilk bulgusu olarak ortaya çıkabilmektedir.Anahtar sözcükler: Epilepsi; hiperglisemi. SummaryEpilepsia partialis continua is generally epileptic seizures, resistant to treatment, consisting of clonic jerks localized to one side of the body that may last from hours to months. In the adult population, brain ischemic lesions, extensive lesions and infections should be ruled out of the etiology. The etiology of easier-to-diagnose metabolic disorders, especially hyperosmolar nonketotic hyperglycemia, should not be forgotten. This is because a significant number of nonketotic hyperglycemia cases develop epilepsia partialis continua; in fact in some patients without diabetes diagnosis, it may be the first finding of diabetes.

show abstract

Epilepsia partialis continua successfully treated with levetiracetam

Cited by 6 publications

References 6 publications

What is the evidence to use new intravenous AEDs in status epilepticus?

What is the evidence to use new intravenous AEDs in status epilepticus?

Successful treatment of epilepsia partialis continua with perampanel: two pediatric cases

An Etiological Cause of Epilepsia Partialis Continua that Should Not be Forgotten: Hyperglycemia

Contact Info

Product

Resources

About